LEN
52
2
HBAN
54
4
NTRS
30
5
RF
45
2
KMI
48
-3
PXD
53
3
USB
40
4
WMT
66
4
SRCL
50
3
SPG
51
3
CHK
27
7
NAVI
33
-7
DAL
72
3
HAS
59
4
EBAY
49
2
HBI
18
-5
AEE
45
2
VNO
65
2
EXPE
56
-8
MMC
51
-2
LEN
52
2
HBAN
54
4
NTRS
30
5
RF
45
2
KMI
48
-3
PXD
53
3
USB
40
4
WMT
66
4
SRCL
50
3
SPG
51
3
CHK
27
7
NAVI
33
-7
DAL
72
3
HAS
59
4
EBAY
49
2
HBI
18
-5
AEE
45
2
VNO
65
2
EXPE
56
-8
MMC
51
-2
Financhill
Back

Cytokinetics 10K Form

Sell
39

CYTK
Cytokinetics

Last Price:
65.57
Seasonality Move:
9.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-03 10Q CYTK/Cytokinetics Quarterly
2023-08-03 10Q CYTK/Cytokinetics Quarterly
2023-05-05 10Q CYTK/Cytokinetics Quarterly
2022-11-04 10Q CYTK/Cytokinetics Quarterly
2022-08-05 10Q CYTK/Cytokinetics Quarterly
2022-05-06 10Q CYTK/Cytokinetics Quarterly

Receive CYTK News And Ratings

See the #1 stock for the next 7 days that we like better than CYTK

CYTK Financial Statistics

Sales & Book Value

Annual Sales: $7.53M
Cash Flow: $-74.11M
Price / Cash Flow: 0
Annual Sales: $-3.80
Price / Book: 0

Profitability

EPS (TTM): -5.45000
Net Income (TTM): $-526.24M
Gross Margin: $-322.59M
Return on Equity: 0%
Return on Assets: -61.92%

Cytokinetics Earnings Forecast

Key Cytokinetics Financial Ratios

  • The Gross Profit Margin over the past 18 years for CYTK is -4,284.10%.
  • The Selling, General & Administrative Expenses for CYTK have been equal to 2,305.60% of Gross Profit Margin.
  • The Research & Development expenses have been 227.10% of Revenue.
  • The Interest Expense is -10.96% of Operating Income.
  • The Net Earning history of CYTK is -6,988.63% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 12 years.

Cytokinetics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CYTK
CUSIP: 23282W
Website: cytokinetics.com

Debt

Debt-to-Equity Ratio: -1.6
Current Ratio: 6.12
Quick Ratio: 6

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CYTK Technical Analysis vs Fundamental Analysis

Sell
39
Cytokinetics (CYTK) is a Sell

Is Cytokinetics a Buy or a Sell?

  • Cytokinetics stock is rated a Sell
    The current Cytokinetics [CYTK] share price is $65.57. The Score for CYTK is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.